5248042022-04-012022-06-305248042022-04-012022-06-30in-bse-fin:OtherExpenses1Member5248042022-04-012022-06-30in-bse-fin:OtherExpenses2Member5248042022-04-012022-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

524804

AUROPHARMA

NOTLISTED

INE406A01037

AUROBINDO PHARMA LIMITED

Equity

2022-04-01

2023-03-31

2022-08-11

2022-08-03

INR

Millions

First quarter

Single segment

Pharmaceutical Products

2022-08-11

14:30:00

2022-08-11

17:15:00

Not applicable

2022-04-01

2022-06-30

Unaudited

Standalone

27869200000

387100000

28256300000

14715200000

388400000

45200000

4143400000

78500000

1030500000

6154400000

26555600000

1700700000

569000000

-89900000

479100000

1221600000

4200000

1225800000

585900000

2.08

Notes: 1. The above financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. The above standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 11, 2022. The statutory auditors have carried out limited review of the above results for the quarter ended June 30, 2022. An unmodified report has been issued by them thereon. 3. The Company operates in only one reportable segment viz., Pharmaceutical Products. 4. a) The Board of Directors of the Company at its meeting held on March 28, 2022 approved the acquisition of business including certain assets of Veritaz Healthcare Limited (Veritaz). Consequently the Company entered into a definitive agreement with Veritaz for the said acquisition for total consideration of Rs.1,710 and obtained control effective April 1, 2022 over such business and assets. b) The Board of Directors of the Company at its meeting held on June 17, 2022 approved investment in GLS Pharma Limited (GLS) through subscription of 2,04,819 equity shares for an aggregate consideration of Rs.93.5 (constituting 17% of the equity share capital of GLS) and acquisition of 4,09,339 equity shares from the selling shareholders for an aggregate consideration of Rs.187 (constituting of 34% of equity share capital of GLS). During the quarter, the Company subscribed to 2,04,819 equity shares of GLS consequent to execution of share subscription and purchase agreement. Post the quarter end on satisfaction of the closing conditions, the Company acquired the additional 4,09,339 equity shares on August 8, 2022. c) During the previous year, pursuant to Board approvals obtained, the following units were transferred within the Group: (i) The undertaking of Unit 10 located at Multiproduct Special Economic Zone, Naidupet, Mandal, SPSR Nellore District, Andhra Pradesh, transferred to its wholly-owned subsidiary APL Healthcare Limited through a slump sale w.e.f April 1, 2021.

Foreign exchange loss (net)

125700000

Other expenses

6028700000

Notes: contiued from Financial Results (ii) The undertaking of Unit-4 of the Company located at Pashamylaram, Pattancheru Mandal, Sangareddy district, Telangana, transferred to Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company w.e.f. July 1, 2021. (iii) The undertaking of Unit-16 of the Company located at TSIIC, SEZ, Polepally Village, Jadcherla Mandal, Mahbubnagar district, Telangana, transferred to Wytells Pharma Private Limited, a wholly owned step-down subsidiary of the Company and 100% subsidiary of Eugia Pharma Specialities Limited w.e.f June 1, 2021. (iv) The undertaking of Unit 18 of the Company located at Survey No.69, 70, 71 & 72, Indrakaran Village, Kandi Mandal, Sangareddy District - 502203, Telangana, to Auro Vaccines Private Limited, a wholly owned subsidiary of the Company. This transfer is aimed at segregation of the vaccines business and subsidiarization of vaccines business in a special purpose vehicle. The slump sale of Unit 18 was effective from January 1, 2022. Consequent to the above transfers\acquisitions, the results of the current quarter are strictly not comparable to the previous quarters. 5. Profit before tax includes exceptional items of Rs.747.1 for the quarter and year ended March 31, 2022 representing impairment of investment relating to a subsidiary. 6. During the quarter ended March 31, 2022, the Company elected to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised provision for income tax for the year ended March 31, 2022 and re-measured its deferred tax assets / liabilities based on the rate prescribed in the said Section. The impact of this change has been recognised in the statement of profit and loss over the period from April 1, 2021 to March 31, 2022. 7. The figures for the quarter ended March 31, 2022 are the balancing figures of the audited financials for the year ended March 31, 2022 and unaudited the year to date published results for the nine months ended December 31, 2021. The standalone financials results of the Company for the quarter ended June 30, 2021 and quarter ended March 31, 2022 were reviewed by the predecessor auditors (M/s BSR & Associates LLP, Chartered Accountants), who had expressed an unmodified review conclusion. The standalone financial results of the Company for the year ended March 31, 2022 were audited by the predecessor auditors (M/S BSR & Associates LLP, Chartered Accountants), who had expressed an unmodified audit opinion.

Remeasurement of defined benefit liability

5600000

1400000